Clinical Trial Goal
To find out:
- The highest dose of sonrotoclax and zanubrutinib that's safe to give
- If the combination of sonrotoclax and zanubrutinib is safe and works well to treat B-NHL that has relapsed or is refractory in persons of ethnic or racial minority
You may be able to join this trial if you:
- Are 18 years old or older
- Have B-NHL that has relapsed or is refractory. Some examples include:
- Chronic lymphocytic leukemia (CLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Marginal zone lymphoma (MZL)
- Mantle cell lymphoma (MCL)
- Small lymphocytic lymphoma (SLL)
- Are of any of the following self-identified racial or ethnic groups:
- American Indian/Native Alaskan
- Black or African American
- Hispanic or Latino
- Non-Hispanic Asian
- Non-Hispanic White
- Pacific Islander/Native Hawaiian
- Do not have active graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Sonrotoclax is a small molecule inhibitor that blocks BTK in certain cells.
Zanubrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Zanubrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Sonrotoclax – A pill that you take by mouth 1 time each day
- Zanubrutinib – A pill that you take by mouth 1 time each day
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has not yet approved sonrotoclax.
Locations
City of Hope Medical CenterRECRUITING
Duarte, California
Geoffrey Shouse, 626-239-5289, gshouse@coh.org
Sponsors
collaborator: National Cancer Institute (NCI), lead: City of Hope Medical Center
